申请人:BRITISH TECHNOLOGY GROUP LIMITED
公开号:EP0409499A3
公开(公告)日:1991-03-27
Compounds of formula II:
wherein n is 0, 1 or 2, R₁, R₂, R₃ and R₄ are each separately selected from hydrogen, unsubstituted acyclic aliphatic hydrocarbon groups having a maximum of six carbon atoms and C₁₋₆ alkyl groups substituted by a hydroxy group or a C₁₋₆ alkoxy group, or one of R₁ and R₂ and one of R₃ and R₄ is hydrogen and the others are a trimethylene, tetramethylene or pentamethylene bridging group, and R₅ as hydrogen or an unsubstituted acyclic aliphatic hydrocarbon group having a maximum of six carbon atoms, but with the provisos that (a) when n is 0 the combinations R₁ = R₂ = R₃ = R₄ = R₅ = H and R₁ = R₂ = R₃ = R₅ = H, R₄ = methyl are excluded, and (b) when n is 0, R₁, R₃ and R₅ are each hydrogen, and each of R₂ and R₄ is other than hydrogen the compound is in other than the meso or erythro configuration, or a salt thereof formed with a physiologically acceptable inorganic or organic acid, are of use in therapy, particularly as cardioprotective agents.
化合物II的公式:其中n为0、1或2,R₁、R₂、R₃和R₄均分别选自氢、最多具有六个碳原子的非取代的脂肪族烃基和被羟基或C₁₋₆烷氧基取代的C₁₋₆烷基,或者R₁和R₂中的一个和R₃和R₄中的一个是氢,其余的是三亚甲基、四亚甲基或五亚甲基桥连基,而R₅为氢或最多具有六个碳原子的非取代的脂肪族烃基,但须符合以下条件:(a)当n为0时,排除R₁ = R₂ = R₃ = R₄ = R₅ = H和R₁ = R₂ = R₃ = R₅ = H,R₄ = 甲基的组合;(b)当n为0时,R₁、R₃和R₅均为氢,而R₂和R₄中的每一个都不是氢,则化合物不在meso或erythro构型中,或者与生理上可接受的无机或有机酸形成的盐,在治疗中具有用途,特别是作为心脏保护剂。